Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 7Not yet recruiting 6Completed 3Withdrawn 2Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 1 2Neurofibroma, Plexiform 2Peripheral Nervous System Diseases 1Neoplasms, Nerve Tissue 1Heredodegenerative Disorders, Nervous System 1Gallbladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

AZD 6244 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neurofibromatosis 1 × AZD 6244 × Clear all
NCT05825365 2023-08-14

PROTECT

AstraZeneca

Phase 2 Withdrawn
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡